Top Fully Remote Biotech Companies (65)
Don't see your company?
Create a company profile
Causaly amplifies human cognitive abilities to expand the boundaries of discovery towards making the best decisions in Biomedicine. To achieve this, we are teaching computers to read all knowledge ever published and develop an interface that allows humans to answer questions they can’t ask anywhere else.
Altos Labs™ is a biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine. The company comprises a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission. Altos has operations in the San Francisco Bay Area and San Diego, and in Cambridge, UK, with significant collaborations in Japan. Note: Altos Labs will not ask you to download a messaging app for an interview or outlay your own money to get started as an employee. If this sounds like your interaction with people claiming to be with Altos, it is not legitimate and has nothing to do with Altos.
Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence, focus on quality and customers. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.5 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.
Parachute is a new kind of plasma donation company that allows individuals to earn money while creating life-saving medicine. Plasma is used to create medicine that treats chronic illnesses, including immune disorders, liver disease, bleeding disorders, and cancer. Right now, there’s a severe plasma shortage, which is impacting patients’ access to these life-saving treatments
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit scorpiontx.com.
Please note that this company page is no longer updated. Meet us at https://www.linkedin.com/company/bio-rad-antibodies. As of May 17 2016, AbD Serotec, a Bio-Rad company changed its name to Bio-Rad. Following this re-branding, we created a new LinkedIn showcase page that features all the latest news, updates and useful resources from the antibody team at Bio-Rad. Please follow us on this new page (https://www.linkedin.com/company/bio-rad-antibodies) to keep in touch with us on LinkedIn.
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. We’re building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine. Founded by experts in the fields of genetic medicine and RNA development and delivery, we have a dynamic operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders.
Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies. Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates and one oncology product candidate in clinical development. The company continues to expand into additional therapeutic areas to address unmet patient needs. Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey.
AB Enzymes is an industrial biotech company specialized in enzymes and their applications. The company is part of Associated British Foods and represented worldwide. Our offices are located in Brazil, China Germany, Finland, Singapore and USA. Our products range from food grade enzymes for baking and beverages, grains and vegetable oil seeds processing, to enzymes for animal feed and technical applications: pulp & paper, textiles and laundry detergents. We partner with our diverse and unique customers to support them in their process optimization needs.
The Public Health Company (PHC Global) is developing the first global biosecurity platform to provide enterprises a SaaS-enabled service for the management of bio-risks. PHC combines world-class expertise with cutting edge technology to be the global solution to enterprise risk management. PHC focuses on intersecting physical world threats across diverse use-cases to deliver actionable and predictive intelligence that enables dynamic risk management with unprecedented speed and scale
Okanagan Specialty Fruits (OSF) began as a small, dynamic agricultural biotechnology company based in Summerland, British Columbia, Canada. Founded in 1996, OSF specializes in developing tree fruit varieties with novel attributes that benefit fruit producers and consumers alike. OSF is one of the first firms to pursue the use of biotechnology to deliver product innovations to the tree fruit industry. Our Leadership OSF is led by apple and cherry grower Neal Carter. Through his work across the globe as a bioresource engineer, Neal became convinced of the opportunities offered by biotechnology. OSF’s world-class science team works collaboratively with many of the world’s leading tree fruit research institutions. Our Vision OSF will change the way people think about and experience produce; our creative product development and commercialization expertise will open the door to novel, exciting, specialized foods that support the evolving healthy diet choices of today’s consumer. Our Mission To develop safe, high-quality tree fruit cultivars that provide growers, processors, wholesalers, retailers, foodservice and consumers with improvements in quality and productivity; and to successfully market and commercialize these products. A revolutionary innovation: Arctic® apples OSF’s flagship project is the development and commercialization of nonbrowning Arctic® apples. Arctic® apples’ nonbrowning trait offers valuable benefits for all members of the apple supply chain, from growers to consumers. OSF holds a worldwide license on the ability to regulate the expression of polyphenol oxidase (PPO) genes to control enzymatic browning in tree fruits, and we are patent holders of the technology that enables us to do so. By reducing the expression of PPO, OSF is developing tree fruits with inhibited enzymatic browning.
Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders
_0.jpg)
OneStudyTeam, a member of the Reify Health family, provides the cloud-based platform StudyTeam to accelerate the development of new and life-saving therapies. StudyTeam brings research site workflows online and enables sites, sponsors, and other key stakeholders to work together more effectively using common technology. The suite of StudyTeam solutions reduces site burden and helps sites pre-screen and enroll more patients, provides sponsors with end-to-end visibility into recruitment activity across all channels, and guides sites in conducting the trial for patients who have been enrolled. StudyTeam is trusted by the largest global biopharmaceutical companies, used in over 5,000 research sites, and is available in over 100 countries. One mission. One team. That’s OneStudyTeam
.jpg)
Lightship is your complete solution for decentralized clinical trials. We built our virtual-first clinical trial model from the ground up, allowing patients to participate in clinical trials from the comfort of home. Come join the team perfecting the way clinical trials are done!
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect and communicate with the world around them. For more than a century, the Demant Group has played a vital part in developing innovative technologies and know-how to help improve people’s hearing and health. In every aspect, from hearing devices, hearing implants and diagnostic equipment to hearing care all over the world, Demant is active and engaged. A growing business in intelligent audio solutions for gaming and office communication is also a significant part of the Group. The Demant Group operates in a global market with companies in more than 30 countries, employs more than 14,500 staff and generates annual revenue of DKK 14 billion. Our products are sold in more than 130 countries where we create life-changing differences through hearing health. Listed on the Nasdaq Copenhagen stock exchange as one of the 25 most traded shares in terms of free floated market capitalisation, also known as the C25 index, Demant is the parent company behind the commercial successes of such world-renowned brands as Oticon, Bernafon, Sonic, Audika, Oticon Medical, MAICO, Interacoustics, Amplivox, Grason-Stadler, MedRx and Sennheiser Communications. William Demant Invest A/S, a company wholly owned by William Demant Foundation, holds the majority of shares in Demant A/S, providing stability and strength for the long haul.
Climate change is the challenge of our generation. As innovators, we believe disruptive technology can bring performant solutions to the most dire challenges we face as a society. As we seek a more respectful way of living on our planet, nature itself has much to offer and teach us, starting with feeding the world of tomorrow with better nutrients - for animals, people and our planet - through insects. At Innovafeed, we are committed to inventing efficient technologies that reproduce Nature's processes on a large scale. By building a circular and zero waste agri-food chain replicating insect's role in nature, we want to reinvent our way of living with higher quality, sustainability and resilience, for everyone. We are a team of pragmatic dreamers who believe performance and positive impact can go hand in hand to reshape the world we leave to future generations.
Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 61,000 staff across a network of over 1,000 independent companies in 59 countries, operating 940 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 33% each year (in compound average) to reach €6.7 billion in 2021.
Pardes is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. By capitalizing on emerging patient-friendly innovations from telehealth to new at-home diagnostic tools, Pardes is cultivating and harvesting the fruits of systemic change. We are on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
iCarbonX is a technology company that is changing how people monitor and understand their health status and optimize their lives. We are building the platform and tools for digitizing, analyzing, and understanding life, and delivering intelligent products and applications—designed for every aspect and stage of life—to help everyone make smarter choices, every day. We’re inspired by every life on this planet, and by a commitment to apply intelligence not just to data, but to the ethical use of that data. Our mission is to bring people together to improve the human condition. We believe we must go beyond genetics to help people understand not just who they are, but how they are. We’re answering the “how” by combining biological and behavioral data with artificial intelligence in a network where people can learn from their own experience and from others like them, creating a global map of human health across cultures and continents that delivers new information and new choices, for life.
Work Your Passion. Live Your Purpose.
